Kiniksa Pharmaceuticals (KNSA) Presents At 41st Annual Healthcare Conference - Slideshow

Pharmacokinetic Simulations PHARMACOKINETICS (PK) LEAD-IN PROOF-OF-CONCEPT AMENDED COHORT 3 (Proof of Concept) 0 200 400 600 800 Addressable US Prevalence (in thousands) 14 KPL-404: Potentially Best-in-Class, Subcutaneously Delivered Monoclonal Antibody Inhibitor 10 11 COHORTS 1-2 (PK Lead-In) Pacific Region (Excluding Japan) Kiniksa is also eligible to receive royalties on annual net sales ranging from low-double digits to mid-teens, before fulfilling upstream financial obligations 16 • Quickly took asset ...